Christos Nousias

Christos Nousias

Auto-generated profile, based on publicly available information

Christos Nousias

IMGT®, IGH, Univ Montpellier, CNRS

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 November 2025 in mAbs
Verified
Journal Article
Open access
TMTaciana Manso
Taciana Manso
GSGaoussou Sanou
Gaoussou Sanou
CNChristos Nousias
Christos Nousias
IMImene Maalem
Imene Maalem
FBFrançois Boutin
François Boutin
Sofia KossidaSofia Kossida
Sofia Kossida
Monoclonal antibodies (mAbs) and fusion proteins for immune applications (FPIA) play a crucial role in treating autoimmune diseases and cancers by targeting cell-surface proteins and triggering multiple immune mechanisms. These functions are mediated by the crystallizable fragment (Fc) region of mAbs and fusion proteins, whose interaction with Fc gamma receptors (FcγRs) can be modulated through Fc amino acid (AA) engineering. To aid research in this area, we developed the IMGT/FcVariantsExplorer tool (https://www.imgt.org/fcvariantsexplorer/) to identify engineered AA changes or variants within the Fc region in mAb and fusion proteins sequences from IMGT/2Dstructure-DB, the AA sequence database of IMGT®, the international ImMunoGeneTics information system®. We used the IMGT® nomenclature of engineered Fc variants involved in antibody effector properties and formats, applying a standardized classification in five categories: 'Effector,' 'Half-life,' 'Physicochemical properties,' 'Structure,' and 'Hybrid.' We analyzed sequences from 1,107 mAbs and fusion proteins, identifying 483 entries with Fc AA changes, resulting in 211 unique Fc variants in the dataset. We also used web scraping to retrieve associated biological data from literature. All data have been integrated into IMGT/mAb-DB, with links to sequences in IMGT/2Dstructure-DB, enabling users to query Fc variants by their 'Category' or 'Effect.' This curated dataset reveals key trends in antibody engineering.

7 September 2025 in bioRxiv
Verified
Preprint
Open access
TMTaciana Manso
Taciana Manso
GSGaoussou Sanou
Gaoussou Sanou
CNChristos Nousias
Christos Nousias
IMImene Maalem
Imene Maalem
FBFrançois Boutin
François Boutin
Sofia KossidaSofia Kossida
Sofia Kossida
Monoclonal antibodies (mAbs) and fusion proteins for immune applications (FPIA) play a crucial role in treating autoimmune diseases and cancers by targeting cell-surface proteins and triggering multiple immune mechanisms. These functions are mediated by the fragment crystallizable (Fc) region of mAbs and fusion proteins, whose interaction with Fc gamma receptors (FcγRs) can be modulated through Fc amino acid (AA) engineering. To address this, we developed the IMGT/FcVariantsExplorer tool ( https://www.imgt.org/fcvariantsexplorer/ ) to identify AA changes within the Fc region in mAb and fusion proteins sequences from IMGT/2Dstructure-DB, the AA sequence database of IMGT®, the international ImMunoGeneTics information system®. We used the IMGT® nomenclature of engineered Fc variants involved in antibody effector properties and formats, applying a standardized classification in five categories: ‘Effector’, ‘Half-life’, ‘Physicochemical properties’, ‘Structure’, and ‘Hybrid’. We analyzed sequences of 1,107 mAbs and fusion proteins, identifying 483 entries with Fc AA changes, resulting in 211 unique Fc variants in the dataset. We also used web scraping to retrieve associated biological data from literature. All data have been integrated into IMGT/mAb-DB, with links to sequences in IMGT/2Dstructure-DB, enabling users to query Fc variants by their ‘Category’ or ‘Effect’. This curated dataset reveals key trends in antibody engineering.